Gram-negative lipopolysaccharide (LPS or endotoxin), the major component of the outer membrane of Gram-negative bacteria, is thought to be a key molecule in the induction of sepsis. LPS causes the production and release from host effector cells of various pro-inflammatory cytokines and other mediators of sepsis, such as nitric oxide and prostaglandins. The degree to which these mediators are released depends, in part, on the amount of LPS that is presented to CD14-bearing effector cells such as monocytes, macrophages, and polymorphonuclear leukocytes. Therefore, it is possible that factors that affect the amount of LPS that is released in vivo may modulate the inflammatory response associated with Gram-negative infection.
INTRODUCTION
Evidence from in vitro experiments and animal and human studies indicate that antibiotic therapy may induce the release of endotoxin from the outer membrane of Gram-negative bacteria. Antibiotics that bind preferentially to penicillin-binding protein-2 (PBP-2) -such as imipenem -are associated with little release of endotoxin, while antibiotics that preferentially bind to PBP-3 -such as ceftazidime -are associated with far greater release of endotoxin. We conducted a randomized, multicenter, double-blind study comparing imipenem to ceftazidime in patients with urinary tract infections caused by Gram-negative bacilli associated with signs and symptoms of systemic inflammation. A total of 33 patients were randomized to receive either imipenem (n = 14) or ceftazidime (n = 19) for initial treatment for urosepsis. No differences in plasma endotoxin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) or urine endotoxin, IL-6 or IL-8 levels were found between the two treatment groups within the first 8 h after antibiotic administration. We conclude that, if differences exist with respect to endotoxin release by these two antimicrobial agents, these differences are not readily demonstrable in this clinical study with carefully defined patients with Gram-negative urinary tract infections.
Ample experimental evidence has accumulated to show that antibiotics may differentially release LPS from Gramnegative organisms. β-Lactam antibiotics that bind preferentially to penicillin-binding protein-2 (PBP-2), such as imipenem, tend to cause rapid killing and spheroplast formation of Gram-negative rods with relatively little release of LPS. In contrast, β-lactam antibiotics that bind to PBP-3, such as ceftazidime, cause disordered cell-wall synthesis which is associated with the development of filamentous forms, and the release of large quantities of LPS. 1, 2 Treatment of Gram-negative bacilli with antibiotics that cause filamentous growth results in the production of large amounts of tumor necrosis factor-α (TNF-α) from human monocytes in vitro 3 and ex vivo in whole human blood. 4 In these experiments, the amount of TNF-α produced correlated with the extent of LPS released and TNF-α production was dramatically diminished in the presence of inhibitors of LPS such as polymyxin B or taurolidine. 3, 4 These observations suggest that LPS released by antibiotics may have a significant impact on the inflammatory response to Gram-negative infections in humans. In support of this concept, cerebrospinal fluid levels of LPS and cytokines rise in children and rabbits with Gram-negative meningitis after antibiotic administration. 5, 6 Corticosteroids blunt the cytokine response to released LPS in a rabbit model of meningitis 6 and, when administered prior to cefotaxime, corticosteroids reduced the morbidity in children with Hemophilus influenzae meningitis. 7 Animal and human experiments have been done to test the hypothesis that antibiotics associated with the release of lower amounts of endotoxin result in the generation of lower levels of pro-inflammatory cytokines and better outcomes. In a mouse model of Gram-negative sepsis, mice sensitized to LPS with D-galactosamine and then challenged with either Escherichia coli or Pseudomonas aeruginosa by intraperitoneal injection had significantly better survival when treated with imipenem compared to ceftazidime. The difference in outcome was evident even though both antibiotics were virtually equally effective in sterilizing blood and peritoneal fluid. 8 In a clinical trial of patients with Gram-negative urosepsis, there was a trend toward lower levels of endotoxin and pro-inflammatory cytokines in serum and urine in imipenem-treated, compared to ceftazidime-treated, patients at 4 h, but this did not reach statistical significance. 9 The kinetics of cytokine release in response to LPS suggest that a more detailed investigation concentrating on the period of time immediately after the first dose of antibiotic is warranted. For example, following injection of human volunteers with a single dose of endotoxin, serum TNF-α levels peak between 1-3 h and become undetectable within 5 h. 10 Therefore, focusing the investigation around this time period would be useful in detecting maximum concentrations of cytokines released in response to antibiotics during therapy of Gram-negative urosepsis. The present study was designed to determine if urine and plasma cytokine and endotoxin levels in patients with Gram-negative urosepsis would be lower in patients treated with imipenem compared with ceftazidime. A randomized, double-blind, multicenter trial was undertaken to test this hypothesis.
PATIENTS AND METHODS

Patient selection
All procedures were reviewed and approved by the Human Subjects Committee at each of the participating institutions (see Appendix). Informed consent was obtained from each patient participating in the study. We selected patients with suspected Gram-negative urosepsis (pyelonephritis) who met the following criteria: age >18 years; typical symptoms of a urinary tract infection (UTI); a urinalysis with >10 leukocytes/high power field (hpf) and <5 epithelial cells/hpf; Gram-negative organisms found on urine Gram's stain; and two of the following -heart rate >90, white-cell blood count (WBC) >10,000/mm 3 , or oral temperature > 38°C. Patients were excluded for any of the following: (i) antibiotic use within the previous 7 days; (ii) expected survival of less than 1 week; (iii) a history of adverse reaction to β-lactam antibiotics; (iv) the presence of major underlying illness, such as AIDS, malignancy or severe immunosuppression; (v) a creatinine clearance of <30 ml/min; (vi) pregnancy or nursing; (vii) use of corticosteroids or other immunosuppressive agents within the previous 3 months; (vii) a history of seizures; or (ix) participation in any investigational drug trial within the previous 30 days.
Treatment regimen
Patients were randomized in a double-blind fashion to receive a single dose of either imipenem/cilastatin 500 mg or ceftazidime 1000 mg in 100 ml of 0.9% NaCl, given i.v. over 30 min. A centralized randomization code was used. The study pharmacist at each center prepared the study medications. The study period concluded 8 h after infusion of the study drug. At that point, patients were treated at the discretion of the physician in charge of their care.
Laboratory testing and clinical monitoring
Prior to infusion of the study drug (time 0), urine and two specimens of blood were collected for culture. Identification of bacterial isolates and antimicrobial susceptibility testing were performed using standard laboratory techniques in each center's clinical microbiology laboratories.
All relevant blood and urine isolates were submitted to a central laboratory to confirm susceptibility to both antibiotics.
Oral temperature, respirations, mean arterial pressure (MAP), and heart rate were recorded at baseline (within 30 min prior to infusion of the study drug), and again at 1-2 h, 3-4 h, and 8 h post dose. Baseline values for serum sodium, potassium, creatinine, and bicarbonate were determined. Blood was also collected for determination of WBC, endotoxin and cytokine levels at baseline, and 1-2 h, 3-4 h, and 8h post dose. Urine was collected in endotoxin-free containers for determination of endotoxin, IL-6, IL-8 and creatinine levels at baseline and 2-3 h, 5-6 h, and 8-10 h post dose. Clinical and laboratory parameters were used to determine the APACHE II score 11 (in most patients, pH and PO 2 were not determined and were, therefore, not included in the calculations for any patients).
Collection of plasma for endotoxin and cytokine levels
For determination of endotoxin levels, blood was collected in endotoxin-free tubes containing heparin sulfate (Chromogenix, Franklin, OH, USA) and immediately placed on ice. Within 30 min of collection, the sample was centrifuged at 3000 rpm for 10 min at 4°C and then stored at -70°C. For determination of cytokine levels, blood was anticoagulated with citrate, centrifuged as above, and 2 ml of plasma transferred to each of two cryo vials and frozen at -70°C.
Assays
Endotoxin was determined via a turbidimetric quantitative Limulus amebocyte lysate assay. Plasma and urine samples were diluted 1:10 in pyrogen-free water and heated at 75°C for 5 min to remove inhibitors of the Limulus reaction. Endotoxin analysis was run in parallel with standard control samples diluted in plasma, and the measurement of each sample was calculated on the basis of rate of increasing turbidity of the Limulus reagents added to the sample (Associates of Cape Cod, Woods Hole, MA, USA). Plasma TNF-α and IL-6, and urine IL-6 and IL-8 were assayed by EIA (Genzyme, Cambridge, MA, USA and Endogen, Boston, MA, USA). The dilutional effects of urine were corrected by expressing urine endotoxin and cytokine values in proportion to the urinary creatinine concentration within individual samples.
Statistical analysis
Summary values were calculated using the mean and standard deviation values for normally distributed data.
Baseline comparability between the two treatment groups was assessed by the Student's t-test for continuous variables or chi-square test for categorical variables. Plasma endotoxin, IL-6, IL-8 and TNF-α values over the first 8 h of treatment were analyzed by the calculation of the area under the curve (AUC) and the maximum concentration (C max ). A multiple analysis of variance (MANOVA) was employed to compare treatment groups with respect to AUC and C max . For non-normally distributed data, comparisons within groups were performed using the generalized Wilcoxon test. Comparisons between treatment groups at each time point were performed using the Wilcoxon Two Sample test (Kruskall-Wallis test for two groups).
RESULTS
Patients
There were 14 patients in the imipenem-treated group (mean age: 45.1 ± 20.7 years) and 19 patients in the ceftazidime-treated group (mean age: 40.0 ± 17.9 years). There was one male in each group. Mean APACHE II scores were 7.6 ± 4.5 and 6.1 ± 3.7 (P = 0.32) for imipenem-and ceftazidime-treated patients ( Table 1) . One patient was randomized to the imipenem group but withdrew consent before blood and urine samples were obtained. This patient was excluded from the analysis. All other patients completed the 8 h study period. The patients were without underlying illness. All patients were diagnosed with Gram-negative bacillary urinary tract infections based on symptoms, signs, urinalysis and urine Gram's stain. 
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Vital signs
There were no significant differences in temperature, mean arterial blood pressure, or heart rate at any time point (Fig. 1 ). There was a slight rise (<0.5°C) in temperature in both groups at 4 h, and this was paralleled by a slight rise in heart rate. The mean arterial pressure remained essentially unchanged in both groups throughout the study period.
Bacteriology
Urine cultures for all 19 ceftazidime-treated patients and for 13 of the 14 imipenem-treated patients were positive for E. coli. For one patient in the imipenem-treated group, the urine culture was considered contaminated. However, this patient's blood culture was positive for Proteus mirabilis. Five other patients in this group had blood cultures positive for E. coli. Four patients in the ceftazidime-treated group had blood cultures positive for E. coli. Overall, blood cultures were positive in 43% of imipenem-treated patients and in 21% of ceftazidimetreated patients (P = 0.25; Table 1 ). All organisms isolated from urine and blood cultures were susceptible to both imipenem and ceftazidime.
Endotoxin levels
For each time point and within each group, plasma and urine endotoxin levels were highly variable and not normally distributed. For this reason, data are presented as median values with error bars representing the 25th and 75th% quartile ranges (Figs 2A & 3A) . Median plasma and urine endotoxin values were not significantly different between the two groups at any time point. A slight increase in plasma endotoxin was seen for the ceftazidime-treated group at 2 h and for the imipenem group at 8 h, but these were not significant increases compared to baseline. When only bacteremic patients were considered, plasma LPS levels were lower in imipenem-treated versus ceftazidime-treated patients at the first two time points, but were higher at the last two time points (mean and median values). These differences were not statistically significant. A clear decline in urine endotoxin levels was seen in both groups over the 8-h period. Comparison of AUC for endotoxin content of plasma or urine demonstrated no significant differences between the two groups.
Cytokine levels
As observed for endotoxin, levels for all cytokines assayed were highly variable and not normally distributed. These results are, therefore, presented as median values with error bars representing the 25th and 75th% quartile ranges. Plasma IL-6 levels (Fig. 2B) for the ceftazidimetreated group rose from a median value of 0 to peak at 4 h and then declined back to 0 at 8 h. Plasma IL-6 levels for patients in the imipenem-treated group were higher at 8 h than at time 0. As indicated by the lower error bars, at any time point, at least 25% of the patients had no detectable IL-6. There was no significant difference between the two groups at any time point. Values for urine IL-6 were not significantly different between the 28 Luchi two groups at any time. Comparison of AUC for the content of any cytokine in plasma or urine demonstrated no significant differences between the two groups. Plasma TNF-α (Fig. 2C) was not detected in any of the imipenem-treated patients and only sporadically in 3 of the 19 ceftazidime-treated patients.
Urine IL-8 levels (Fig. 3C ) showed a clear, continuous downward trend in the imipenem-treated group. Baseline levels in the ceftazidime-treated patients were lower and remained essentially unchanged throughout the study period. Differences between these groups were not statistically significant.
For bacteremic patients, mean and median plasma TNFα values were 0 at all time points. Mean and median values of plasma IL-6 were higher in imipenem-treated patients compared to ceftazidime-treated patients at all time points, and did not correlate with plasma endotoxin levels.
DISCUSSION
We conducted a randomized, double-blind clinical trial in patients with Gram-negative bacterial urinary tract infections with systemic symptoms to determine if the Differential endotoxin release 29 release of endotoxin and generation of pro-inflammatory cytokines could be modulated by choice of antibiotics. Previous studies have demonstrated that antibiotics vary widely in their propensity to release endotoxin from Gram-negative bacteria. 1 We determined that the use of imipenem (associated with low levels of endotoxin release in vitro) or ceftazidime (associated with higher levels of endotoxin release in vitro) did not cause a significant difference in endotoxin or cytokine levels in blood or urine over the 8-h study period. There was also no significant difference in temperature, mean arterial blood pressure, and heart rate between the two groups of patients at any time during the study period. We conclude that, in the treatment of patients who are moderately ill with Gram-negative bacterial urinary tract infections, the choice of β-lactam antibiotic did not make a difference in plasma or urine endotoxin levels or in the levels of cytokines tested in this study. There is also no clinically significant difference as measured by temperature, mean arterial blood pressure or heart rate.
The patients in both groups were similar. All but one of the patients in each group were female and close in age. There were no major underlying illnesses. The severity of illness was not significantly different as determined by APACHE II scores. Although bacteremia was more common in the imipenem-treated group (43%) compared to the ceftazidime-treated group (27%), this difference was not statistically significant. Apart from the small sample size, there is no obvious explanation for this difference. All but one of the 33 patients had E. coli as the infecting organism. It is interesting to note that just prior to infusion of the study drug, urine endotoxin levels were higher in the imipenem-treated group of patients. There is no clear explanation for this observation.
Prins et al 9 compared imipenem versus ceftazidime in patients with urosepsis. In this study, slower defervescence was noted in patients treated with ceftazidime, but this was statistically significant only at 4 h. At 4 h of treatment, the blood endotoxin level declined in all 3 endotoxemic patients receiving imipenem, but increased in 2 of the 4 endotoxemic patients receiving ceftazidime. Urine endotoxin levels had declined to approximately the same values in both groups at 4 h and were virtually undetectable by 24 h. Plasma and urine cytokine levels increased by 10-40% in ceftazidime treated patients at 4 h, but not in imipenemtreated patients. These differences were not statistically significant. As in our study, there was a very large variation in cytokine levels between patients. Neither of these studies demonstrated significant differences in endotoxin or cytokine levels in blood or urine, and no substantial differences were seen in clinical parameters, such as temperature. After collection of blood and urine at baseline and 4 h, no additional samples were collected until 24 h post dose.
The results of these two clinical trials are different from what would be expected from several in vitro and animal studies showing that antibiotics associated with substantial release of endotoxin result in the generation of higher levels of pro-inflammatory cytokines [1] [2] [3] [4] and that this can be associated with decreased survival. 8 One possible explanation for this apparent discrepancy is that, in the clinical studies of urinary tract infections, 2/3 of patients were not bacteremic. In order for an effect to be seen, bacteria may need to be present in the blood. In support of this concept, a recent study conducted in Thailand comparing imipenem to ceftazidime in patients septicemic with Burkholderia pseudomallei demonstrated significantly higher levels of plasma endotoxin and proinflammatory cytokines. 12 However, in our study, even when patients with bacteremia were analyzed separately, there were still no significant differences in endotoxin release or cytokine generation between ceftazidime-and imipenem-treated patients. In addition, a recent study of patients with Gram-negative bacteremia found no differences in cytokine or endotoxin levels or outcome related to antibiotic-induced endotoxin releasing potential. 13 Local release of endotoxin or cytokine release in the kidney may be more difficult to detect because analysis of urine is an indirect measurement of events within the renal parenchyma. In addition, detectable increases in cytokine generation may require substantial release of endotoxin. Although endotoxin release of this magnitude in response to antibiotics has been documented in vitro, 9 there is no evidence that this extent of endotoxin release occurs in vivo. Therefore, it is possible that differences in endotoxin release in vivo seldom reach the threshold required to achieve significant differences in the generation of proinflammatory cytokines.
CONCLUSIONS
In summary, this comparison of imipenem versus ceftazidime was conducted in a uniform population of otherwise healthy patients moderately ill with pyelonephritis. There were no significant differences at any time point in clinical parameters (temperature, blood pressure, or heart rate) or plasma and urine endotoxin and cytokine levels. The results do not support the hypothesis that differential antibiotic-induced endotoxin release is of clinical significance in pyelonephritis. The relevance of this in vitro phenomenon to other diseases, such as meningitis, may require further investigation.
